Latest News

• 

  PathWest makes Australia’s top companies’ list for the midsize category 17 April 2025 PathWest is honoured to be named on LinkedIn’s 2025 Top Companies list in Australia for the midsize category – a prestigious recognition celebrating leading workplaces with fewer than 5,000 employees where professionals can thrive and grow their careers. PathWest is the only Western Australian entity to be named for 2025. "This recognition reflects our ongoing commitment to fostering a positive, inclusive, and empowering workplace where every team member feels supported and inspired to reach their full potential", said Dr Narelle Hadlow, PathWest Chief Executive. "Thank you to our incredible team for improving the health, wellbeing, and safety of our communities every day – this achievement is yours." Learn more
• 

  Sendaway Testing for Neuronal Antibodies 13 March 2025 PathWest wishes to advise that the process for send away testing for neuronal antibodies require discussion with, and approval by, an immunopathologist. If the testing is thought to be clinically appropriate, and where relevant first tier testing is negative, testing will be organised and the costs covered by PathWest laboratory. For testing that is deemed to be required, but is discorda...
• 

  2024 Festive Season Opening Hours 17 December 2024 PathWest collection centres will be closed on the following dates: 2024 Wednesday 25 December Thursday 26 December Sunday 29 December. 2025 Wednesday 1 January. Collection centres that are normally closed on weekends will be closed as usual on Saturday 28 December 2024. Find your nearest collection centre. PathWest wishes you a safe and happy festive season!
• 

  Recognition of Service Awards 2024 21 November 2024 On Wednesday, 20 November, PathWest recognised the significant contributions of staff who have served 20, 30, and 40 years in public pathology, acknowledging the dedication and expertise that have helped shape our organisation over the decades. The event commenced with a Welcome to Country by Mr Nigel Wilkes Snr. Both our Chief Executive, Dr Narelle Hadlow and Board Chair, Angie Paskevicius, deliv...
• 

  Rhesus D Non-Invasive Prenatal Testing now available at PathWest 04 November 2024 Commenced on 4 November 2024, the Rhesus D Non-invasive Prenatal Testing (RHD NIPT) screening test is now available for pregnant patients who are Rhesus D-negative, do not already have anti-D antibodies and are fully covered under Medicare. The test should be done between 20 to 32 weeks at a PathWest collection centre and requires a special collection tube. For further information on the test, pl...